Is Molycorp Back?

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Over the course of this week, shares of Molycorp Inc. (NYSE: MCP) have more than doubled. Monday shares increased 40%, and Tuesday shares grew by another 67%. This begs the question of whether this cult stock is back and if it can get past the New York Stock Exchange’s $1 rule — the stock has been under $1 since the end of November.

What drove shares up this time was a report that Molycorp’s Mountain Pass California facility increased its rare earth production in the fourth quarter to nearly double the previous quarter.

In the fourth quarter, Mountain Pass produced 1,328 metric tons (MT) of rare earth oxide equivalent production compared to 1,034 MT in the previous year. The full year production for 2014 was 4,785 MT compared to 3,473 MT in 2013.

The higher production volumes expected at Mountain Pass in 2015 should coincide with the relatively strong demand that Molycorp is seeing for products such as the magnetic rare earth material neodymium/praseodymium, lanthanum, and light rare earth concentrate.

ALSO READ: Why Cliffs Natural Resources Could Go Much Lower

Geoff Bedford, president and CEO of Molycorp, said:

We were pleased to see our production increase in the fourth quarter relative to the preceding quarter and year-on-year. Optimization at Mountain Pass is ongoing, but our fourth quarter production demonstrates momentum in the right direction. Rare earth pricing softened in fourth quarter with market uncertainty surrounding release of final details of China’s ongoing reforms to rare earth mining, separation, and export regulatory policies. However, given the relatively strong internal and external demand we are seeing for many Mountain Pass products, continuing to boost production there is a top operational priority.

A recent analyst call for Molycorp came from DA Davidson. The firm downgraded Molycorp to a Neutral rating from Buy, and lowered its price target to $0.38 from $4.00, on January 23. This was the lowest call on the street and it implies downside of 52.5% from Tuesday’s close of $0.80.

Shares of Molycorp were down 7% at $0.74 in the second half of Wednesday’s trading. The stock has a consensus analyst price target of $1.12 and a 52-week trading range of $0.28 to $5.62. Molycorp hit a peak of roughly $75 in 2011.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618